瑞桥鼎科集团与日本株式会社钟化集团达成i-ED弹簧圈分销合作

February 20, 2025 -EverBridge group and Kaneka Medix Corporation (“Kaneka”or “Kaneka group” ) announced that they have reached a distribution cooperation for Kaneka Group's i-ED embolization coils.

根据协议条款，瑞桥鼎科集团将成为Kaneka集团旗下i-ED栓塞弹簧圈在大中华区的代理经销商，负责该产品在大中华区（不包括香港、澳门、台湾、上海、广东、浙江、四川、天津、云南）的销售和推广工作。

According to the terms of the agreement, EverBridge will become the distributor of Kaneka Group's i-ED embolization coils in the Greater China Region, responsible for the sales and promotion of the product in this region (excluding Hong Kong, Macao, Taiwan, Shanghai, Guangdong, Zhejiang, Sichuan, Tianjin and Yunnan).

颅内动脉瘤是出血性脑血管疾病的常见病变。动脉瘤如果破裂出血，患者会出现颅内压升高和颅内水肿，甚至会诱发脑疝，对呼吸中枢、循环中枢产生严重影响，进而导致死亡。目前，颅内动脉瘤主要通过弹簧圈栓塞术、血流导向密网支架置入术等介入治疗方案来防止颅内动脉瘤破裂或再次出血。Kaneka集团旗下的i-ED栓塞弹簧圈已在日本使用近二十年，其具有多个专利设计特征：包括Wave-SR波浪状缝线、PVA解脱区设计和低记忆形状等，使i-ED 弹簧圈区别于市场上的其他弹簧圈。

Intracranial aneurysms are common lesions of hemorrhagic cerebrovascular diseases. If an aneurysm ruptures and bleeds, the patient will experience increased intracranial pressure and edema, and may even induce brain herniation, which will have a serious impact on the respiratory and circulatory centers and lead to death. At present, intracranial aneurysms are mainly treated with neuro-interventional treatments such as coil embolization and flow diverter implantation to prevent intracranial aneurysm rupture or re-bleeding. The i-ED embolization coil developed byKaneka Group has been used in Japan for nearly two decades. It has multiple patented design features: including Wave-SR sutures, PVA detachment zone design and low memory shape, which distinguish the i-ED coil from other coils on the market.

此次战略合作是瑞桥鼎科集团神经科学业务线布局中的一个重要决策，通过与Kaneka集团的合作，进一步补强了瑞桥鼎科神经科学业务线产品组合。随着产品种类扩展以及市场覆盖面扩大，瑞桥鼎科集团神经科学业务将拥有更显著的竞争优势，也能为患者提供更卓越的产品与健康福祉。

This strategic collaboration represents a pivotal initiative in EverBridge Group's neuroscience business division development plan. By establishing a synergistic partnership with the Kaneka Group, EverBridge has achieved a comprehensive enhancement of its neuroscience product portfolio. The diversified product matrix and expanded market coverage will significantly elevate the business unit's competitive positioning in global markets. This strategic alignment not only reinforces EverBridge's leadership in neurological therapeutics innovation, but also enables it to deliver enhanced therapeutic value to patients worldwide through optimized product availability and clinical outcomes.